Stručni rad

TREATMENT OF MULTIPLE SCLEROSIS WITH CLADRIBINE – A RETROSPECTIVE ONE-YEAR ANALYSIS AT DEPARTMENT OF NEUROLOGY, SESTRE MILOSRDNICE UNIVERSITY HOSPITAL CENTRE IN ZAGREB

NEVENA GRBIĆ orcid.org/0000-0003-1537-3734 ; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
MILJENKA-JELENA JURAŠIĆ ; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
LUCIJA ZADRO MATOVINA ; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
IRIS ZAVOREO orcid.org/0000-0001-9358-1665 ; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb,Sveučilište u Zagrebu, Kineziološki fakultet, Zagreb, Hrvatska
IVANA HUSTIĆ orcid.org/0000-0002-4481-1281 ; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Hrvatska
VANJA BAŠIĆ KES ; Klinički bolnički centar Sestre milosrdnice, Klinika za neurologiju, Referentni centar Ministarstva zdravstva za neuroimunologiju i neurogenetiku, Zagreb, Sveučilište u Zagrebu, Stomatološki fakultet, Zagreb, Sveučilište Josipa Jurja Strossmayera u Osijeku, Medicinski fakultet, Osijek, Hrvatska

Sažetak

Cladribine (Mavenclad®, Merck Europe, The Netherlands) is a drug used in patients with highly active multiple sclerosis (MS). The exact mechanism is not known but it is considered that drug affects the function of DNA and mitochondria leading to apoptosis of lymphocytes. The effi cacy and safety of cladribine were evaluated in a randomized, double-blind, placebocontrolled clinical trial (CLARITY study) and later on in studies resulting from this study. Patients with relapsing-remitting MS (RRMS) who received cladribine had a statistically signifi cant improvement in the annual rate of relapse, proportion of relapse-free patients and proportion of patients without persistent disability. The aim of this study was to analyze MS patients treated with cladribine at the Department of Neurology, Sestre milosrdnice University Hospital Centre and to compare the results with the existing fi ndings on the drug. This retrospective one-year analysis included patients eligible for cladribine treatment. In total, cladribine was administered to 15 patients. Of these, 46% of patients had previously received fi rst-line immunomodulatory therapy and 53% of patients had not previously undergone immunomodulatory therapy. After one year, before applying second drug cycle, there were no relapses in 66% of patients. In total, there were 20% of side effects, mostly skin reactions. Analysis of data on our group of patients revealed that some of the results were consistent with the CLARITY study, and certain data were approximate to this study. Also, drug administration was associated with a small proportion of side effects. However, additional analysis in a greater patient sample is required, and we plan to extend this study and provide new information in the future.

Ključne riječi

multiple sclerosis; cladribine; treatment; experience

Hrčak ID:

244547

URI

https://hrcak.srce.hr/244547

Datum izdavanja:

6.10.2020.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.920 *